MIR505

Summary

MIR505 (microRNA 505, HGNC:32140) is a microRNA gene on chromosome Xq27.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574508 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32140
Approved symbol	MIR505
Name	microRNA 505
Location	Xq27.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-505
Ensembl gene	ENSG00000207633
Ensembl biotype	miRNA
OMIM	301053
Entrez	574508
RNAcentral	URS000072D134 — miRNA, 84 nt, 19 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384901

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384901 — 1 exons

Exon	Start	End
ENSE00001499908	139924148	139924231

Expression profiles

Bgee: expression breadth broad, 52 present calls, max score 82.31.

Top tissues by expression

52 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
liver	UBERON:0002107	82.31	gold quality
blood	UBERON:0000178	80.65	gold quality
kidney	UBERON:0002113	78.67	gold quality
lung	UBERON:0002048	78.18	gold quality
gastrocnemius	UBERON:0001388	76.87	gold quality
stomach	UBERON:0000945	76.32	gold quality
calcaneal tendon	UBERON:0003701	75.78	gold quality
heart	UBERON:0000948	75.48	gold quality
monocyte	CL:0000576	74.28	gold quality
intestine	UBERON:0000160	73.70	gold quality
right atrium auricular region	UBERON:0006631	72.93	gold quality
minor salivary gland	UBERON:0001830	72.87	gold quality
adult mammalian kidney	UBERON:0000082	71.73	gold quality
endometrium	UBERON:0001295	71.18	gold quality
body of stomach	UBERON:0001161	70.56	gold quality
multicellular organism	UBERON:0000468	70.39	gold quality
nucleus accumbens	UBERON:0001882	69.14	gold quality
colon	UBERON:0001155	68.69	gold quality
muscle layer of sigmoid colon	UBERON:0035805	68.31	gold quality
esophagus mucosa	UBERON:0002469	68.24	gold quality
body of pancreas	UBERON:0001150	68.03	gold quality
tibial artery	UBERON:0007610	67.97	gold quality
popliteal artery	UBERON:0002250	67.79	gold quality
urinary bladder	UBERON:0001255	67.33	gold quality
subcutaneous adipose tissue	UBERON:0002190	66.91	gold quality
left lobe of thyroid gland	UBERON:0001120	66.73	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	66.48	gold quality
right coronary artery	UBERON:0001625	66.03	gold quality
right hemisphere of cerebellum	UBERON:0014890	66.02	gold quality
cerebellum	UBERON:0002037	66.01	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.95

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 32)

• miR-505 is a novel tumor suppressive miRNA and inhibits cell proliferation by inducing apoptosis (PMID:22051041)
• MicroRNA-505 was found to be a novel circulating signature of hypertension. (PMID:25449503)
• Results identified rs111638916 SNP in the PSMD10 3’-UTR as a risk factor for gastric cancer (GC) and acted as a tumor promoting factor. SNP rs111638916 was also regulated by miR-505, resulting in its up-regulation in patients with GA and AA genotypes. (PMID:26394032)
• miR-505 acts as tumor suppressor in endometrial cancer by regulating TGF-alpha. (PMID:26832151)
• Notably, High-Mobility Group Box 1 knockdown apparently promoted cell proliferation and invasion in MHCC97. SIGNIFICANCE: We investigated that MiR-505 regulates proliferation and invasion in MHCC97 cells via targeting High-Mobility Group Box 1 (PMID:27259809)
• miR-505-5p and miR-193b-3p have the potential to serve as a biomarker for the assessment of imatinib therapy response in newly diagnosed CML patients. (PMID:28093001)
• Low cervical tumor expression of miR-505 was associated with patients’ advanced tumor stage and short survival. (PMID:28577497)
• Authors showed that Mir505-3p was capable of inhibiting tumor proliferation driven by SRSF1 in two neural tumor cell lines, Neuro-2a (N2a) and U251, exclusively in serum-reduced condition. Authors observed that the protein level of SRSF1 was gradually promoted by increasing concentration of serum. (PMID:29120871)
• MACs from Familial hypercholesterolemia (FH)-MACs have an inflammatory phenotype that is characterized by the up-regulation of CCR3, CCR4, and CXCR1 under the control of miR-505-3p. These results suggest a chronic inflammatory condition in FH innate immunity cells that is not reverted by standard lipid-lowering treatment (PMID:29457550)
• MiR-505 mediated MTX resistance, propagation, cell cycle and metastasis by targeting RASSF8 in colorectal cancer (PMID:29726011)
• HMGB1 knockdown and miR-505 overexpression promoted ADM-induced DNA damage in HCC cells. (PMID:29803174)
• miR-505, by inversely regulating NPDC1 may have a functional role in regulating human Parkinson’s disease (PMID:30025813)
• Results showed that miR505 is downregulated in bone metastatic prostate cancer (PCa) tissues. miR505 negatively regulated TGF-beta signaling by directly targeting downstream effectors of TGFbeta signaling, SMAD2 and SMAD3, further inhibiting the invasion and migration abilities of PCa cells. (PMID:30365141)
• In donation after circulatory death (DCD) grafts, high levels of miR-505-3p in preservation fluid are associated with increased risk of delayed graft function after kidney transplantation. (PMID:30444806)
• the data revealed the novel role and target of miR505 in NSCLC cells, which may provide novel insights regarding its role in the carcinogenesis of NSCLC and its potential values for clinical applications. (PMID:30628663)
• Study find that miR505 was significantly increased in lung adenocarcinoma (LA). miR505 functions as an oncogene, promoting lung cancer cell proliferation and inhibiting cancer cell apoptosis via the targeting of TP53AIP1. Finally, it was confirmed that miR505 in plasma extracellular vesicles (EVs) could be delivered to lung cancer cells, inhibiting cell apoptosis and promoting cell proliferation by targeting TP53AIP1. (PMID:30864684)
• MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R. (PMID:31160483)
• Low miR505 expression is associated with prostate cancer progression. (PMID:31322225)
• Data showed that miR-505 was correlated with cervical carcinoma (CC) histology grade, tumor size, FIGO stage, and lymph node metastasis. miR-505 inhibits TGF-beta1-induced migration, invasion, and EMT. LncRNA-CTS is a molecular sponge for miR-505 in CC. (PMID:31499118)
• LEF-AS1 participates in occurrence of colorectal cancer through adsorbing miR-505 and promoting KIF3B expression. (PMID:31773695)
• The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells. (PMID:31885317)
• miR-505 inhibits proliferation of osteosarcoma via HMGB1. (PMID:32348630)
• LncRNA ZEB1-AS1 promotes pancreatic cancer progression by regulating miR-505-3p/TRIB2 axis. (PMID:32513531)
• microR-505/heterogeneous nuclear ribonucleoprotein M inhibits hepatocellular carcinoma cell proliferation and induces cell apoptosis through the Wnt/beta-catenin signaling pathway. (PMID:32940078)
• MiR-505 inhibits prostate cancer cell invasion, metastasis and epithelial-to-mesenchymal transition through targeting HMGB-1. (PMID:33099950)
• Ultrasound Microbubble-Mediated microRNA-505 Regulates Cervical Cancer Cell Growth via AKT2. (PMID:33123457)
• lncRNA KTN1AS1 promotes glioma cell proliferation and invasion by negatively regulating miR5053p. (PMID:33125151)
• The long noncoding RNA DLGAP1-AS2 facilitates cholangiocarcinoma progression via miR-505 and GALNT10. (PMID:33301605)
• miR-505 inhibits replication of Borna disease virus 1 via inhibition of HMGB1-mediated autophagy. (PMID:35060474)
• Long Non-coding RNA KTN1-AS1 Targets miR-505 to Promote Glioblastoma Progression. (PMID:36762036)
• Upregulation of lncRNA PTOV1-AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR-505. (PMID:37352125)
• HuR-induced circ_0082319 contributes to hepatocellular carcinoma by elevating PTK2 through miR-505-3p. (PMID:37878047)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir505	ENSMUSG00000070081

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.